Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP)
CONCLUSION: CTLA-4 CT 60 A/G may affect the susceptibility of ITP, but both CTLA-4 + 49 A/G and CT60 A/G did not impact the response of patients with ITP to different lines of therapy.PMID:38485815 | PMC:PMC10917709 | DOI:10.1007/s44313-024-00011-z (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Doaa Mohamed El Demerdash Maha Mohamed Saber Alia Ayad Kareeman Gomaa Mohamed Abdelkader Morad Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP)
CONCLUSION: CTLA-4 CT 60 A/G may affect the susceptibility of ITP, but both CTLA-4 + 49 A/G and CT60 A/G did not impact the response of patients with ITP to different lines of therapy.PMID:38485815 | PMC:PMC10917709 | DOI:10.1007/s44313-024-00011-z (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Doaa Mohamed El Demerdash Maha Mohamed Saber Alia Ayad Kareeman Gomaa Mohamed Abdelkader Morad Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP)
CONCLUSION: CTLA-4 CT 60 A/G may affect the susceptibility of ITP, but both CTLA-4 + 49 A/G and CT60 A/G did not impact the response of patients with ITP to different lines of therapy.PMID:38485815 | PMC:PMC10917709 | DOI:10.1007/s44313-024-00011-z (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Doaa Mohamed El Demerdash Maha Mohamed Saber Alia Ayad Kareeman Gomaa Mohamed Abdelkader Morad Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP)
CONCLUSION: CTLA-4 CT 60 A/G may affect the susceptibility of ITP, but both CTLA-4 + 49 A/G and CT60 A/G did not impact the response of patients with ITP to different lines of therapy.PMID:38485815 | PMC:PMC10917709 | DOI:10.1007/s44313-024-00011-z (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Doaa Mohamed El Demerdash Maha Mohamed Saber Alia Ayad Kareeman Gomaa Mohamed Abdelkader Morad Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP)
CONCLUSION: CTLA-4 CT 60 A/G may affect the susceptibility of ITP, but both CTLA-4 + 49 A/G and CT60 A/G did not impact the response of patients with ITP to different lines of therapy.PMID:38485815 | PMC:PMC10917709 | DOI:10.1007/s44313-024-00011-z (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Doaa Mohamed El Demerdash Maha Mohamed Saber Alia Ayad Kareeman Gomaa Mohamed Abdelkader Morad Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
